Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors

Abstract:
An interdisciplinary team of researchers at Brigham and Women's Hospital (BWH) and the Harvard-MIT Division of Health Sciences and Technology has demonstrated a better way to deliver cancer drugs directly to tumors by using specially engineered nanoparticles that can inhibit a signaling pathway and deliver a higher concentration of medication to the specific area. Details of their work appear on April 20, in an early online edition of the Proceedings of the National Academy of Science.

Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors

Boston, MA | Posted on April 20th, 2009

An interdisciplinary team of researchers at Brigham and Women's Hospital (BWH) and the Harvard-MIT Division of Health Sciences and Technology has demonstrated a better way to deliver cancer drugs directly to tumors by using specially engineered nanoparticles that can inhibit a signaling pathway and deliver a higher concentration of medication to the specific area. Details of their work appear on April 20, in an early online edition of the Proceedings of the National Academy of Science.

The team constructed the nanoparticles from a biodegradable, biocompatable, Food and Drug Administration-approved polymer which they chemically engineered to deliver a MAPK inhibitor. By inhibiting the MAPK signaling pathway, which is involved in a majority of human tumors, the nanoparticles hinder the multiplication of cancerous cells and predispose those cells to the cytotoxic effects of chemotherapeutic drugs. The team also modified the polymer to increase drug loading 20 fold, which overcomes a current drawback in nanomedicine, low efficiency of drug loading.

"Current chemotherapeutic drugs must be administered in high concentration throughout the body in order to destroy tumor cells, translating to high toxicity and discomfort for the patient, mainly due to the effects on normal cells," said Rania Harfouche, one lead author of the study, and fellow in the Health Sciences and Technology (HST) Division at BWH. These newly engineered nanoparticles would, however, selectively target the tumor cells and predispose them to chemotherapeutic drugs. "This will allow for lower drug concentration to be used, and provide opportunity for more potent treatments with lesser side-effects for the patient."

The combination of nanoparticles and the cancer drug cisplatin proved successful in preventing the growth of cancerous skin and lung cells and also induced cell death. When researchers gave the same combination to mice with melanoma, it inhibited tumor growth and enhanced the efficacy of the cancer drug. The entire tumors regressed in fifty percent of mice, compared with none in the group receiving cisplatin and the inhibitor without nanoparticles.

In previous work, the group demonstrated that a combination of two drugs delivered with a nanoparticle could exert superior anti-cancer effects. However, most cancers converge into a few pathways for survival and uncontrolled division. "We thought a better strategy might be to target these pathways using nanoparticles, almost like shutting the escape route before exposing the cancer to the drugs," said lead author Sudipta Basu, fellow in the HST Division at BWH.

"The nanoparticles target pathways involved in multiple cancer types and can be applied to a diverse set of cancers, including hard-to-treat cancers, such as breast, pancreatic and liver cancer," noted senior study author Shiladitya Sengupta, PhD, of the Department of Medicine at BWH. "The potential to add homing beacons on the surface of the nanoparticles can increase the efficiency of selectively targeting specific tumors and abolish off target side-effects".

The team also included BWH research fellows Dr. Shivani Soni, Dr. Geetanjali Chimote, and Dr. Raghunath Mashelkar, a polymer chemist and visiting professor at HST from the National Chemical Laboratories in India. This research was funded by grants from the Coulter Foundation, the Mary Kay Ash Charitable Foundation and the Department of Defense BCRP.

####

About Brigham and Women's Hospital
Brigham and Women's Hospital (BWH) is a 777-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. In July of 2008, the hospital opened the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 860 physician-investigators and renowned biomedical scientists and faculty supported by more than $416 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative.

For more information, please click here

Contacts:
Holly Brown-Ayers
Brigham and Women's Hospital
617-534-1603

Copyright © Vocus PRW Holdings, LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Nanomedicine

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Discoveries

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Nano-sized Chip "Sniffs Out" Explosives Far Better than Trained Dogs: TAU researcher's groundbreaking sensor detects miniscule concentrations of hazardous materials in the air July 23rd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

Announcements

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE